Anti-CD3 antibody-induced activated killer cells: cytokines as the additional signals for activation of killer cells in effector phase to mediate slow lysis.
This study examines the role of cytokines in activating the effector cells to mediate slow lysis. After activation of splenocytes by alpha CD3, further culturing the cells in the absence of alpha CD3 resulted in the generation of activated killer cells (CD3-AK-) to mediate slow lysis. In contrast to fast lysis which was not affected by a PKC inhibitor H-7, slow lysis was inhibited. These findings suggested that a PKC-dependent activation phase preceded the lytic phase in slow lysis. To explore the mechanism for activating the lytic machinery in slow lysis, we examined the roles of cytokines in these reactions. First, it was found that alpha IL-2 or an alpha IL-2/alpha IL-4 combination inhibited slow lysis but had no effect on fast lysis. Secondly, IL-2, IL-4, or TNF alpha converted a noncytolytic CD3-AK- cells to mediate slow lysis, but they did not augment fast lysis. IL-2 and IL-4 had additive effect, and TNF alpha synergized with IL-2 to further augment the CD3-AK- cytolytic activity. Exogenous IL-6 and INF did not have any appreciable effect on the cytolytic activity of the killer cells. Besides TNF alpha, these cytokines were not directly cytotoxic to the target cells, indicating that they were not cytotoxic factors per se. Treatment with cycloheximide for 24 hr abrogated the cytolytic activities of CD3-AK cells, suggesting that a cytotoxic factor(s) was continuously synthesized to be stored in activated killer cells and was catabolized within 24 hr. Our results indicated that in the effector phase of slow lysis, after activating the CD3-AK- cells by the first signal (appropriate target cells), IL-2 and/or IL-4 appeared to be the second signal to initiate a cascade of events which triggered the release of other cytokines (e.g., TNF). This process resembles the secondary (memory) type of immune response. These events lead to full activation of the killer cells and converted the preformed cytotoxic factors into active form to initiate the lytic reaction and completed the lytic process.
Ting
C C
CC
Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Hargrove
M E
ME
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D015703:Antigens, CD / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D017252:CD3 Complex; D003513:Cycloheximide / Q000494:pharmacology; D016207:Cytokines / Q000502:physiology*; D003602:Cytotoxicity, Immunologic; D005260:Female; D007378:Interleukins / Q000502:physiology; D007546:Isoquinolines / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D010879:Piperazines / Q000494:pharmacology; D011493:Protein Kinase C / Q000502:physiology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D016207:Cytokines; D007378:Interleukins; D007546:Isoquinolines; D010879:Piperazines; D011948:Receptors, Antigen, T-Cell; D014409:Tumor Necrosis Factor-alpha; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D003513:Cycloheximide; D011493:Protein Kinase C